Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date.

J Hepatocell Carcinoma · 2020 · PMC7501959 · PMID 32984090

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the pembrolizumab arm had longer OS (HR 0.78 [95% CI 0.61–0.99]) and longer PFS (HR 0.78 [95% CI 0.61–0.99]), it did not reach statistical significance per the planned analysis.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.